Are the new weight loss medications the treatment the food industry needs?

Background New weight loss medications, including newer incretin mimetics such as GLP-1 receptor agonists, are likely to revolutionise the treatment of obesity but their effects should be understood not only clinically but also within the food system. Main Body Using the National Institute of Health Body Weight Planner and weight loss data from clinical trials of semaglutide and tirzepatide, we estimated the average daily energy intake before treatment, during the initial weight loss phase, and with long-term sustained treatment. Compared with the average daily energy intake of 2,666 kcal/day before treatment initiation, these treatments are associated with an 18–26% lower energy intake during the initial weight loss phase and a persistent 10–16% lower energy intake thereafter if treatment is sustained. Conclusion This extent of energy intake reduction is small enough to avoid clinical concerns about population-level malnutrition but large enough to alter food demand and underscores the need for the food system to adapt.

Authors

Institutions

Publication Details

Journal
BMC Medicine
Published
2026-11-20
DOI
https://doi.org/10.1186/s12916-026-05329-2
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Are the new weight loss medications the treatment the food industry needs?

Dimitrios A. Koutoukidis, Susan A. Jebb
1 links
BMC Medicine
Pharmacology and Obesity Treatment
article

Are the new weight loss medications the treatment the food industry needs?

Dimitrios A. Koutoukidis, Susan A. Jebb
article en

Abstract

Background New weight loss medications, including newer incretin mimetics such as GLP-1 receptor agonists, are likely to revolutionise the treatment of obesity but their effects should be understood not only clinically but also within the food system. Main Body Using the National Institute of Health Body Weight Planner and weight loss data from clinical trials of semaglutide and tirzepatide, we estimated the average daily energy intake before treatment, during the initial weight loss phase, and with long-term sustained treatment. Compared with the average daily energy intake of 2,666 kcal/day before treatment initiation, these treatments are associated with an 18–26% lower energy intake during the initial weight loss phase and a persistent 10–16% lower energy intake thereafter if treatment is sustained. Conclusion This extent of energy intake reduction is small enough to avoid clinical concerns about population-level malnutrition but large enough to alter food demand and underscores the need for the food system to adapt.

BMC Medicine
University of Oxford (GB)
National Institute for Health and Care Research
Good health and well-being
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Are the new weight loss medications the treatment the food industry needs? — Dimitrios A. Koutoukidis, Susan A. Jebb · BMC Medicine (2026) | TGRS Research Map | TGRS